The cross-talk between mucormycosis, steroids and diabetes mellitus amidst the global contagion of COVID-19

被引:2
作者
Dwivedi, Shrey [1 ]
Choudhary, Princy [1 ]
Gupta, Ayushi [1 ]
Singh, Sangeeta [1 ]
机构
[1] Indian Inst Informat Technol, Dept Appl Sci, Allahabad, Uttar Pradesh, India
关键词
Mucormycosis; mucorales; COVID-19; corticosteroids; diabetes mellitus; hyperglycaemia; ketoacidosis; RHINOCEREBRAL MUCORMYCOSIS; PULMONARY MUCORMYCOSIS; GLYCEMIC CONTROL; EPIDEMIOLOGY; ZYGOMYCOSIS; SYSTEM; SUSCEPTIBILITY; POSACONAZOLE; PATHOGENESIS; ANTIFUNGAL;
D O I
10.1080/1040841X.2022.2052795
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Mucormycosis is an opportunistic fungal disease that targets individuals having an impaired immune system due to a wide array of risk factors including HIV-AIDS, immunosuppressive therapy, diabetes mellitus, etc. The current explosive outbreak of coronavirus disease 2019 (COVID-19) has become the latest threat to such patients who are already susceptible to secondary infections. Physiological outcomes of COVID-19 end up in a cascade of grave alterations to the immunological profile and irreparable harm to their respiratory passage, heart and kidneys. Corticosteroidal treatment facilitates faster recovery and alleviates the adverse pathological effects of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). But clinical reports lend this approach a darker perspective especially if these patients have pre-existing diabetes mellitus. The mucormycotic fungal genera belonging to the order Mucorales not only survive but thrive under the comorbidity of COVID-19 and diabetes, often staying undetected until they have inflicted irreversible damage. Steroidal usage has been noted to be a common thread in the sudden spurt in secondary fungal infections among COVID-19 cases. Once considered a rare occurrence, mucormycosis has now acquired a notoriously lethal status in mainstream medical hierarchy. We set out to investigate whether corticosteroidal therapy against COVID-19 emboldens the development of mucormycosis. We also assess the conditions brought forth by steroidal usage and uncontrolled progression of diabetes in COVID-19 cases and their effect on the susceptibility towards mucormycosis.
引用
收藏
页码:318 / 333
页数:16
相关论文
共 126 条
[1]   Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 [J].
Ackermann, Maximilian ;
Verleden, Stijn E. ;
Kuehnel, Mark ;
Haverich, Axel ;
Welte, Tobias ;
Laenger, Florian ;
Vanstapel, Arno ;
Werlein, Christopher ;
Stark, Helge ;
Tzankov, Alexandar ;
Li, William W. ;
Li, Vincent W. ;
Mentzer, Steven J. ;
Jonigk, Danny .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (02) :120-128
[2]   The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis [J].
Ahmadikia, Kazem ;
Hashemi, Seyed Jamal ;
Khodavaisy, Sadegh ;
Getso, Muhammad Ibrahim ;
Alijani, Neda ;
Badali, Hamid ;
Mirhendi, Hossein ;
Salehi, Mohammadreza ;
Tabari, Azin ;
Mohammadi Ardehali, Mojtaba ;
Kord, Mohammad ;
Roilides, Emmanuel ;
Rezaie, Sassan .
MYCOSES, 2021, 64 (08) :798-808
[3]   Activity of Posaconazole and Other Antifungal Agents against Mucorales Strains Identified by Sequencing of Internal Transcribed Spacers [J].
Alastruey-Izquierdo, Ana ;
Victoria Castelli, Maria ;
Cuesta, Isabel ;
Monzon, Araceli ;
Cuenca-Estrella, Manuel ;
Luis Rodriguez-Tudela, Juan .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (04) :1686-1689
[4]  
Alekseyev Kirill, 2021, J Med Cases, V12, P85, DOI 10.14740/jmc3637
[5]   Study on invasive aspergillosis using galactomannan enzyme immunoassay and determining antifungal drug susceptibility among hospitalized patients with hematologic malignancies or candidates for organ transplantation [J].
Ardi, Pegah ;
Daie-Ghazvini, Roshanak ;
Hashemi, Seyed Jamal ;
Salehi, Mohammad Reza ;
Bakhshi, Heidar ;
Rafat, Zahra ;
Zareei, Mahdi ;
Getso, Muhammad ;
Basiri, Solmaz ;
Sarwestani, Hasti Kamali ;
Boroujeini, Zeinab Borjian ;
Ahmadikia, Kazem .
MICROBIAL PATHOGENESIS, 2020, 147
[6]   A MECHANISM OF SUSCEPTIBILITY TO MUCORMYCOSIS IN DIABETIC-KETOACIDOSIS - TRANSFERRIN AND IRON AVAILABILITY [J].
ARTIS, WM ;
FOUNTAIN, JA ;
DELCHER, HK ;
JONES, HE .
DIABETES, 1982, 31 (12) :1109-1114
[7]   Intercepting the deadly trinity of mucormycosis, diabetes and COVID-19 in India [J].
Banerjee, Mainak ;
Pal, Rimesh ;
Bhadada, Sanjay K. .
POSTGRADUATE MEDICAL JOURNAL, 2022, 98 (E2) :E108-E109
[8]   Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations [J].
Bayram, Nurettin ;
Ozsaygili, Cemal ;
Sav, Hafize ;
Tekin, Yucel ;
Gundogan, Medine ;
Pangal, Emine ;
Cicek, Ayse ;
Ozcan, Ibrahim .
JAPANESE JOURNAL OF OPHTHALMOLOGY, 2021, 65 (04) :515-525
[9]   Managing mucormycosis in diabetic patients: A case report with critical review of the literature [J].
Beiglboeck, Fabian M. ;
Theofilou, Nantia E. ;
Fuchs, Matthias D. ;
Wiesli, Matthias G. ;
Leiggener, Christoph ;
Igelbrink, Sebastian ;
Augello, Marcello .
ORAL DISEASES, 2022, 28 (03) :568-576
[10]  
Bhatt Kinal, 2021, Discoveries (Craiova), V9, pe126, DOI 10.15190/d.2021.5